Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Paeds SAQsclinical-pharmacology-and-therapeutics

Paeds SAQs · clinical-pharmacology-and-therapeutics

Cardiovascular medicines in children — formative SAQs

Formative SAQs on cardiovascular medicines in children: designing a prostaglandin E1 resuscitative plan for a duct-dependent neonate, and building the stepwise pharmacological management of paediatric heart failure with the carvedilol and single-ventricle enalapril trial evidence in mind.

20 marks30 min3 min readVerification in progress

Target exams

RACP General PaediatricsMRCPCH ClinicalRACP DWE
On this page
Study tools

Target exams

RACP General PaediatricsMRCPCH ClinicalRACP DWE
Prompt
Prostaglandin E1 in the duct-dependent neonate, and stepwise heart failure pharmacology

SAQ 1 — A cyanotic neonate and prostaglandin E1 (10 marks, 15 minutes)

Stem: A two-day-old term neonate presents with central cyanosis, tachypnoea and a metabolic acidosis. There is strong clinical suspicion of a duct-dependent congenital heart lesion, and echocardiography is being arranged. Outline the immediate pharmacological management, the dose, the target, and the adverse effects you must prepare for. [10]

Model answer

Immediate action (2 marks). Do not wait for echocardiography. Start an intravenous prostaglandin E1 (alprostadil) infusion at once, because the circulation depends on a patent ductus arteriosus that is closing. Prostaglandin E1 reopens and keeps the duct patent while definitive anatomy-specific management is arranged. Secure intravenous access, give oxygen, and prepare for transfer to a cardiac centre. [10]

Dose and titration (3 marks). Start at 0.01 to 0.05 microgram per kilogram per minute intravenously and titrate upward toward a typical maximum of around 0.1 microgram per kilogram per minute, watching for the response: a rising oxygen saturation, a warming perfusion, and a falling lactate. The target saturation in most duct-dependent cyanotic disease is around 75 to 85 per cent, not a normal saturation, because excessive pulmonary flow steals from the systemic circulation. State that prostaglandin E1 is a bridge, not a treatment. [10]

Adverse effects and preparation (3 marks). Three adverse effects are expected and prepared for. Apnoea is common — have a plan for intubation and ventilation. Fever can mislead the team toward a septic work-up; recognise it as a drug effect. Hypotension is managed with volume and, where needed, a low-dose vasopressor. Recognise that the fever and apnoea are the drug, not the disease. [10]

Safety and disposition (2 marks). Treat the prostaglandin as a bridge to definitive anatomy repair or palliation. Communicate clearly with the family, organise retrieval to a cardiac centre, and document the dose, the titration and the airway plan. Do not allow suspicion of sepsis to delay the prostaglandin, but take appropriate cultures and consider antibiotics alongside. [10]

Paediatrics Fellowship Pro

Continue reading

You have read the opening of this SAQ. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship library.

Sign in to continueSee pricing
References4ShowHide
  1. [2]Shaddy RE, Boucek MM, Hsu DT, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA, 2007.PMID 17848651
  2. [3]Hsu DT, Zak V, Mahony L, et al. Enalapril in infants with single ventricle: results of a multicenter randomized trial. Circulation, 2010.PMID 20625111
  3. [4]Hsu DT, Pearson GD Heart failure in children: part II: diagnosis, treatment, and future directions. Circ Heart Fail, 2009.PMID 19808380
  4. [10]Taksande A, Jameel PZ Critical Congenital Heart Disease in Neonates: A Review Article. Curr Pediatr Rev, 2021.PMID 33605861
Paediatrics Fellowship Pro

$29/ monthor $279 / year

The complete Paediatrics Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousAnalgesics and antipyretics — formative SAQsclinical-pharmacology-and-therapeuticsNextChemotherapy and supportive pharmacology — formative SAQsclinical-pharmacology-and-therapeutics